Does Unasyn Cover Prevotella?
Yes, Unasyn (ampicillin/sulbactam) provides effective coverage against Prevotella species, as the sulbactam component inhibits beta-lactamases commonly produced by these anaerobic bacteria.
Guideline-Based Evidence
The IDSA guidelines for skin and soft tissue infections explicitly recommend ampicillin-sulbactam for human bite wounds, which are commonly infected with Prevotella species along with other oral anaerobes 1. These guidelines specifically note that human bite infections involve "multiple anaerobic organisms, including Fusobacterium, Peptostreptococcus, Prevotella, and Porphyromonas species" and list ampicillin-sulbactam as a first-line treatment option at 1.5-3.0 g every 6 hours 1.
FDA-Approved Indications
The FDA label for Unasyn includes coverage of Bacteroides fragilis and other Bacteroides species for intra-abdominal, gynecological, and skin/soft tissue infections 2. While Prevotella is not explicitly listed in the FDA indications, the drug label confirms activity against anaerobic gram-negative bacilli through sulbactam's beta-lactamase inhibition 2.
Clinical Susceptibility Data
High Susceptibility Rates
Recent multicenter surveillance data demonstrates excellent activity of ampicillin/sulbactam against Prevotella species:
A 2020 Turkish study of 118 Prevotella isolates (13 different species) found only 1 isolate (0.8%) with intermediate resistance to ampicillin/sulbactam, while 57.6% were resistant to ampicillin alone 3. This highlights the critical role of sulbactam in overcoming beta-lactamase-mediated resistance.
A 2018 European multicenter study of 508 Prevotella isolates confirmed that ampicillin/sulbactam "showed good activity" against Prevotella species 4.
Older studies from 2001 and 1994 demonstrated that adding sulbactam to ampicillin maintained effectiveness against beta-lactamase-positive Prevotella strains, with beta-lactamase production detected in 31.9-35.6% of Prevotella isolates 5, 6.
Mechanism of Action
Sulbactam irreversibly inhibits the plasmid-mediated beta-lactamases that Prevotella species commonly produce, thereby restoring ampicillin activity 2. Studies show beta-lactamase production rates of 31.9-68.4% among different Prevotella species, making the beta-lactamase inhibitor component essential 7, 5.
Clinical Dosing Recommendations
For infections involving Prevotella:
- Standard dosing: 1.5-3.0 g IV every 6 hours (equivalent to 1-2 g ampicillin with 0.5-1 g sulbactam) 1
- The IDSA guidelines recommend this regimen specifically for polymicrobial infections involving oral anaerobes including Prevotella 1
Important Caveats
Resistance concerns: While overall susceptibility remains high, the 2020 Turkish study noted emerging intermediate resistance (0.8%), and clinicians should be aware that resistance patterns vary geographically 3. The 2018 multicenter study emphasized "the need for species level identification of clinical Prevotella isolates and periodic monitoring of their susceptibility" 4.
Not for all anaerobes: The 2010 IDSA guidelines for intra-abdominal infections specifically recommend against using ampicillin-sulbactam for community-acquired infections due to high resistance rates among E. coli, though this recommendation pertains to aerobic gram-negative coverage, not anaerobic coverage 1.